User Fee Program Has Not Changed “Risk Threshold,” CDER’s Galson Says
This article was originally published in The Tan Sheet
Executive Summary
FDA sees no evidence of a change in its risk threshold as a result of the user fee program, Center for Drug Evaluation & Research Acting Director Steven Galson said during an April 15 meeting of FDA's Science Board
You may also be interested in...
Drug Safety Board Will Lead To More Advisory Panel Meetings – FDA’s Galson
The advent of FDA's Drug Safety Oversight Board likely will lead to an increase in the number of advisory committee meetings, Center for Drug Evaluation & Research Acting Director Steven Galson said at a meeting of FDA's Science Board April 15
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands